Denali Therapeutics Inc   (DNLI)
Other Ticker:  
Price: $16.8900 $-0.04 -0.236%
Day's High: $17.08 Week Perf: 2.12 %
Day's Low: $ 16.54 30 Day Perf: -1.8 %
Volume (M): 1,205 52 Wk High: $ 33.31
Volume (M$): $ 20,344 52 Wk Avg: $23.37
Open: $16.85 52 Wk Low: $15.45

 Market Capitalization (Millions $) 2,325
 Shares Outstanding (Millions) 138
 Employees 340
 Revenues (TTM) (Millions $) 341
 Net Income (TTM) (Millions $) 330
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 16

Denali Therapeutics Inc
Denali Therapeutics Inc is a biotechnology company that focuses on discovering and developing treatments for neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.
The company was founded in 2015 by a group of leading scientists and drug developers from Genentech, including Ryan Watts, Alex Schuth, and Marc Tessier-Lavigne.
Denali's approach to drug development is based on the use of proprietary technologies such as the Transport Vehicle platform and the Neuroimmunology platform.
The Transport Vehicle platform is designed to allow large molecules such as antibodies to cross the blood-brain barrier, which is essential for treating neurodegenerative diseases.
The Neuroimmunology platform is focused on developing therapies that modulate the immune system's response to neurodegenerative diseases.
Currently, Denali has several drug candidates in its pipeline that are designed to address the underlying biology of neurodegenerative diseases.
One of the company's lead drug candidates is DNL151, an oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is a genetically validated target for Parkinson's disease.
Denali also has a collaboration with Sanofi to develop potential treatments for multiple sclerosis and other neuroinflammatory disorders.
The company is headquartered in South San Francisco, California, and has over 400 employees, including scientists, researchers, and drug developers with extensive experience in the biotechnology industry.
Denali has received over $600 million in funding from leading investors such as Fidelity, Flagship Pioneering, and the Alaska Permanent Fund Corporation.
Overall, Denali is focused on developing breakthrough therapies that have the potential to improve the lives of patients with neurodegenerative diseases.

   Company Address: 161 Oyster Point Blvd South San Francisco 94080 CA
   Company Phone Number: 866-8548   Stock Exchange / Ticker: NASDAQ DNLI


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Unveiling the Potential of Blood-Brain Barrier Crossing Enzyme Replacement Therapies in Lysosomal Storage Diseases: Novel Insights from Denali Therapeutics

Published Wed, Feb 7 2024 1:00 PM UTC

Abstract:Denali Therapeutics, a renowned biopharmaceutical company, recently announced its expansion and promising new data regarding its work on enzyme replacement therapies (ERTs) engineered to traverse the blood-brain barrier (BBB) for treating neurodegenerative and lysosomal storage diseases. This report will specifically focus on the exciting progress the company has ma...

Product Service News

Denali Therapeutics Charts Strategic Roadmap for 2024 with Anticipated Milestones for Expanding Neurodegeneration and Lysosomal Storage Diseases Portfolio

Published Mon, Jan 8 2024 1:01 PM UTC

At the start of the new year, Denali Therapeutics Inc., a biopharmaceutical company operating from South San Francisco, California, has revealed key resolutions and goals for the year 2024. This announcement comes just in time for the 42nd Annual J.P. Morgan Healthcare Conference which is poised to take place on Tuesday, January 9th.Denali Therapeutics is a frontrunner in it...

Denali Therapeutics Inc

Denali Therapeutics Inc experiences a surge in revenue for the first quarter of 2023 despite a decline in net income

Denali Therapeutics Inc is a biotechnology company that is focused on developing therapeutics for neurological diseases. The company's portfolio includes drug candidates for Parkinson's disease, multiple sclerosis, and Alzheimer's disease. Denali Therapeutics Inc aims to harness the power of genetics and molecular biology to create new treatments for these diseases.
Despite achieving a return on average invested assets (ROI) of 6.05% in its first quarter of 2023, Denali Therapeutics Inc's ROI is below its average return on investment. The decline in net income resulted in a decrease in ROI relative to the period ending Dec 31 2022. Within the Healthcare sector, there were five other companies that had a higher return on investment than Denali Therapeutics Inc.


Denali Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com